Search Results 531-540 of 18363 for alopecia

1. Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies - Mayo Clinic

   Participants with Grade 2 neuropathy or Grade 2 alopecia are eligible. - Active idiopathic thrombocytopenic purpura. - Stem cell transplant < 100 days prior ...

2. A Study Of IDRX-42 Versus Sunitinib In Participants With Metastatic And/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib Therapy (StrateGIST 3) - Mayo Clinic

   Note: Treatment-related Grade > 1 alopecia, treatment-related Grade 2 peripheral neuropathy, and treatment-related Grade 2 hypothyroidism on a stable dose ...

3. MC200404, Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Late-stage Metastatic Colorectal Cancer - Mayo Clinic

   Relevant toxicities of prior therapies must have resolved to ≤Grade 1, except for oxaliplatin-related neuropathy or alopecia;; Participant with myocardial ...

4. Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors - Mayo Clinic

   Note: Except patients with ≤ Grade 2 neuropathy or any grade of alopecia. Has tumor(s) invading a major vascular structure (e.g., carotid artery) or other ...

5. A Study to Evaluate Ulixertinib to Treat Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations - Mayo Clinic

   In addition, any drug-related toxicity except alopecia should have recovered to Grade 1 or less. Prior therapy with any ERK inhibitor (e.g., LY3214996 ...

6. A Study to Evaluate a Standard-dose and High- dose Regimen of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Melanoma Brain Metastasis - Mayo Clinic

   Note: Stable chronic conditions (≤ Grade 2) that are not expected to resolve (such as neuropathy, myalgia, alopecia, prior therapy-related endocrinopathies) ...

7. Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer - Mayo Clinic

   ... alopecia); Patients who are receiving any other investigational agents; Patients with symptomatic central nervous system (CNS) metastases or leptomeningeal ...

8. Evaluate The Safety, Tolerability, Pharmacokinetics And Efficacy Of BL-M05D1 In Subjects With Solid Tumors - Mayo Clinic

   ... alopecia and endocrinopathies controlled by replacement therapy that must be Grade ≤2 9. Has no serious cardiac dysfunction, left ventricular ejection ...

9. A Study Of Sonodynamic Therapy With SONALA-001 And Exablate 4000 Type 2.0 In Subjects With Progressive Or Recurrent Glioblastoma Multiforme (RGBM) - Mayo Clinic

   ... Alopecia, lymphopenia, peripheral neuropathy, and ototoxicity ≤Grade 3). Known history of the following conditions: Allergy to gadolinium contrast agents.

10. Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye - Mayo Clinic

    ... alopecia and other non-clinically significant adverse events (AEs); No active brain metastases or epidural disease; patients with brain metastases previously ...